TAMAKA GANGWISH: Open Payments
NPI 1669844916 · HASTINGS, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,008 in 53 payments from 18 companies in 2025. Trend: 2023 $828 · 2024 $1,285 · 2025 $1,008
Food & beverage: $1,008
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $308 |
| AstraZeneca Pharmaceuticals LP | 3 | $148 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Axsome Therapeutics, Inc. | 4 | $58 |
| PFIZER INC. | 2 | $46 |
| Amgen Inc. | 3 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Novo Nordisk Inc | 1 | $25 |
| Abbott Laboratories | 1 | $24 |
Products named: VRAYLAR, AIRSUPRA, REXULTI, CAPLYTA, Auvelity, NURTEC ODT, EVENITY, QULIPTA.
Industry payments across NE — which companies pay providers there.
